Download PDF
Horm Metab Res 2013; 45(01): 9-14
DOI: 10.1055/s-0032-1323680
Original Basic
© Georg Thieme Verlag KG Stuttgart · New York

CCAAT/Enhancer-binding Protein-Homologous Protein Sensitizes to SU5416 by Modulating p21 and PI3K/Akt Signal Pathway in FRO Anaplastic Thyroid Carcinoma Cells

S. H. Kim
1   Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea
,
J. G. Kang
1   Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea
,
C. S. Kim
1   Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea
,
S.-H. Ihm
1   Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea
,
M. G. Choi
1   Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea
,
H. J. Yoo
1   Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea
,
S. J. Lee
1   Division of Endocrinology and Metabolism, Department of Internal Medicine, College of Medicine, Hallym University, Chuncheon, Republic of Korea
› Author Affiliations
Further Information

Publication History

received 17 April 2012

accepted 23 July 2012

Publication Date:
23 August 2012 (online)

Also available at
    Permissions and Reprints

Abstract

SU5416, vascular endothelial cell growth factor receptor inhibitor, suppresses hypoxia-induced angiogenesis, growth, proliferation, and metastasis in cancer cells. CCAAT/enhancer-binding protein-homologous protein (CHOP) has pivotal roles in regulation of growth and survival. In the present study, we evaluated the effects of SU5416 on cell survival, p21, and PI3K/Akt signal pathway in FRO anaplastic thyroid carcinoma (ATC) cells. Moreover, we investigated the roles of CHOP in cell survival under condition of SU5416 treatment in FRO ATC cells. After SU5416 treatment, cell viability, PARP-1, and caspase-3 protein levels were not changed. p53 and p27 protein levels decreased while p21 protein levels increased. Phospho-Akt protein levels were not altered. In SU5416-treated situation, cell viability was not different before and after administration of either p21 siRNA or LY294002 whereas it was lessened after co-administration of p21 siRNA and LY294002. Compared to SU5416 treatment alone, cell viability was reduced with CHOP plasmid but it was unchanged with CHOP siRNA. PARP-1 and caspase-3 protein levels with CHOP plasmid were elevated whereas the protein levels with CHOP siRNA were similar. While CHOP plasmid transfection diminished p21 and phospho-Akt protein levels, CHOP siRNA transfection did not alter the protein levels. In conclusion, these results suggest that CHOP may sensitize FRO ATC cells to SU5416 thereby inhibiting cell survival by modulating p21 and PI3K/Akt signal pathway. Furthermore, these findings imply that CHOP may be a possible candidate as the chemosensitizing factor for induction of cytotoxicity in ATC cells exposed to SU5416.

Key words

anaplastic thyroid carcinoma - SU5416 - CCAAT/enhancer-binding protein-homologous protein - p21 - Akt
 

  • References

  • 1 Akaishi J, Sugino K, Kitagawa W, Nagahama M, Kameyama K, Shimizu K, Ito K, Ito K. Prognostic factors and treatment outcomes of 100 cases of anaplastic thyroid carcinoma. Thyroid 2011; 21: 1183-1189
    CrossrefPubMedGoogle Scholar
  • 2 Smallridge RC, Marlow LA, Copland JA. Anaplastic thyroid cancer: molecular pathogenesis and emerging therapies. Endocr Relat Cancer 2009; 16: 17-44
    PubMedGoogle Scholar
  • 3 Sun L, Tran N, Tang F, App H, Hirth P, McMahon G, Tang C. Synthesis and biological evaluations of 3-substituted indolin-2-ones: a novel class of tyrosine kinase inhibitors that exhibit selectivity toward particular receptor tyrosine kinases. J Med Chem 1998; 41: 2588-2603
    CrossrefPubMedGoogle Scholar
  • 4 Ye C, Sweeny D, Sukbuntherng J, Zhang Q, Tan W, Wong S, Madan A, Ogilvie B, Parkinson A, Antonian L. Distribution, metabolism, and excretion of the anti-angiogenic compound SU5416. Toxicol in Vitro 2006; 20: 154-162
    CrossrefPubMedGoogle Scholar
  • 5 Ban HS, Uno M, Nakamura H. Suppression of hypoxia-induced HIF-1alpha accumulation by VEGFR inhibitors: different profiles of AAL993 versus SU5416 and KRN633. Cancer Lett 2010; 296: 17-26
    CrossrefPubMedGoogle Scholar
  • 6 Knies-Bamforth UE, Fox SB, Poulsom R, Evan GI, Harris AL. c-Myc interacts with hypoxia to induce angiogenesis in vivo by a vascular endothelial growth factor-dependent mechanism. Cancer Res 2004; 64: 6563-6570
    CrossrefPubMedGoogle Scholar
  • 7 Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH, Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G. SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types. Cancer Res 1999; 59: 99-106
    PubMedGoogle Scholar
  • 8 Mendel DB, Laird AD, Smolich BD, Blake RA, Liang C, Hannah AL, Shaheen RM, Ellis LM, Weitman S, Shawver LK, Cherrington JM. Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent. Anticancer Drug Des 2000; 15: 29-41
    PubMedGoogle Scholar
  • 9 Zhong X, Li X, Wang G, Zhu Y, Hu G, Zhao J, Neace C, Ding H, Reed E, Li QQ. Mechanisms underlying the synergistic effect of SU5416 and cisplatin on cytotoxicity in human ovarian tumor cells. Int J Oncol 2004; 25: 445-451
    PubMedGoogle Scholar
  • 10 Glade-Bender J, Kandel JJ, Yamashiro DJ. VEGF blocking therapy in the treatment of cancer. Expert Opin Biol Ther 2003; 3: 263-276
    CrossrefPubMedGoogle Scholar
  • 11 Mologni L, Sala E, Cazzaniga S, Rostagno R, Kuoni T, Puttini M, Bain J, Cleris L, Redaelli S, Riva B, Formelli F, Scapozza L, Gambacorti-Passerini C. Inhibition of RET tyrosine kinase by SU5416. J Mol Endocrinol 2006; 37: 199-212
    CrossrefPubMedGoogle Scholar
  • 12 Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res 2005; 65: 3980-3985
    CrossrefPubMedGoogle Scholar
  • 13 Bonofiglio D, Qi H, Gabriele S, Catalano S, Aquila S, Belmonte M, Ando S. Peroxisome proliferator-activated receptor gamma inhibits follicular and anaplastic thyroid carcinoma cells growth by upregulating p21Cip1/WAF1 gene in a Sp1-dependent manner. Endocr Relat Cancer 2008; 15: 545-557
    CrossrefPubMedGoogle Scholar
  • 14 Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007; 129: 1261-1274
    CrossrefPubMedGoogle Scholar
  • 15 Saito J, Kohn AD, Roth RA, Noguchi Y, Tatsumo I, Hirai A, Suzuki K, Kohn LD, Saji M, Ringel MD. Regulation of FRTL-5 thyroid cell growth by phosphatidylinositol (OH) 3 kinase-dependent Akt-mediated signaling. Thyroid 2001; 11: 339-351
    CrossrefPubMedGoogle Scholar
  • 16 Comalada M, Xaus J, Sanchez E, Valledor AF, Celada A. Macrophage colony-stimulating factor-, granulocyte-macrophage colony-stimulating factor-, or IL-3-dependent survival of macrophages, but not proliferation, requires the expression of p21(Waf1) through the phosphatidylinositol 3-kinase/Akt pathway. Eur J Immunol 2004; 34: 2257-2267
    CrossrefPubMedGoogle Scholar
  • 17 Zhong XS, Zheng JZ, Reed E, Jiang BH. SU5416 inhibited VEGF and HIF-1alpha expression through the PI3K/AKT/p70S6K1 signaling pathway. Biochem Biophys Res Commun 2004; 324: 471-480
    CrossrefPubMedGoogle Scholar
  • 18 Xing M. Genetic alterations in the phosphatidylinositol-3 kinase/Akt pathway in thyroid cancer. Thyroid 2010; 20: 697-706
    CrossrefPubMedGoogle Scholar
  • 19 Oyadomari S, Mori M. Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ 2004; 11: 381-389
    CrossrefPubMedGoogle Scholar
  • 20 Luethy JD, Fargnoli J, Park JS, Fornace Jr AJ, Holbrook NJ. Isolation and characterization of the hamster gadd153 gene: activation of promoter activity by agents that damage DNA. J Biol Chem 1990; 265: 16521-16526
    PubMedGoogle Scholar
  • 21 Fornace Jr AJ, Alamo Jr I, Hollander MC. DNA damage-inducible transcripts in mammalian cells. Proc Natl Acad Sci USA 1988; 85: 8800-8804
    CrossrefPubMedGoogle Scholar
  • 22 Zinszner H, Kuroda M, Wang XZ, Batchvarova N, Lightfoot RT, Remotti H, Stevens JL, Ron D. CHOP is implicated in programmed cell death in response to impaired function of the endoplasmic reticulum. Genes Dev 1998; 12: 982-995
    CrossrefPubMedGoogle Scholar
  • 23 Lee SJ, Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ. Effects of all-trans retinoic acid on sodium/iodide symporter and CCAAT/enhancer-binding protein-homologous protein under condition of endoplasmic reticulum stress in FRTL5 thyroid cells. Horm Metab Res 2011; 43: 331-336
    Article in Thieme ConnectPubMedGoogle Scholar
  • 24 Lee SJ, Kim SH, Kang JG, Kim CS, Ihm SH, Choi MG, Yoo HJ. Alpha-lipoic acid inhibits endoplasmic reticulum stress-induced cell death through PI3K/Akt signaling pathway in FRTL5 thyroid cells. Horm Metab Res 2011; 43: 445-451
    Article in Thieme ConnectPubMedGoogle Scholar
  • 25 Nozaki S, Sledge Jr GW, Nakshatri H. Repression of GADD153/CHOP by NF-kappaB: a possible cellular defense against endoplasmic reticulum stress-induced cell death. Oncogene 2001; 20: 2178-2185
    CrossrefPubMedGoogle Scholar
  • 26 Kim R, Ohi Y, Inoue H, Toge T. Taxotere activates transcription factor AP-1 in association with apoptotic cell death in gastric cancer cell lines. Anticancer Res 1999; 19: 5399-5405
    PubMedGoogle Scholar
  • 27 Kato MA, Finley DJ, Lubitz CC, Zhu B, Moo TA, Loeven MR, Ricci JA, Zarnegar R, Katdare M, Fahey 3rd TJ. Selenium decreases thyroid cancer cell growth by increasing expression of GADD153 and GADD34. Nutr Cancer 2010; 62: 66-73
    PubMedGoogle Scholar
  • 28 Kim R, Ohi Y, Inoue H, Aogi K, Toge T. Introduction of gadd153 gene into gastric cancer cells can modulate sensitivity to anticancer agents in association with apoptosis. Anticancer Res 1999; 19: 1779-1783
    PubMedGoogle Scholar
  • 29 Mihailidou C, Papazian I, Papavassiliou AG, Kiaris H. CHOP-dependent regulation of p21/waf1 during ER stress. Cell Physiol Biochem 2010; 25: 761-766
    CrossrefPubMedGoogle Scholar
  • 30 Xaus J, Cardó M, Valledor AF, Soler C, Lloberas J, Celada A. Interferon gamma induces the expression of p21waf-1 and arrests macrophage cell cycle, preventing induction of apoptosis. Immunity 1999; 11: 103-113
    CrossrefPubMedGoogle Scholar
  • 31 Hyoda K, Hosoi T, Horie N, Okuma Y, Ozawa K, Nomura Y. PI3K-Akt inactivation induced CHOP expression in endoplasmic reticulum-stressed cells. Biochem Biophys Res Commun 2006; 340: 286-290
    CrossrefPubMedGoogle Scholar
  • 32 Bromati CR, Lellis-Santos C, Yamanaka TS, Nogueira TC, Leonelli M, Caperuto LC, Gorjão R, Leite AR, Anhê GF, Bordin S. UPR induces transient burst of apoptosis in islets of early lactating rats through reduced AKT phosphorylation via ATF4/CHOP stimulation of TRB3 expression. Am J Physiol Regul Integr Comp Physiol 2011; 300: R92-R100
    CrossrefPubMedGoogle Scholar
  • 33 Piscazzi A, Costantino E, Maddalena F, Natalicchio MI, Gerardi AMT, Antonetti R, Cignarelli M, Landriscina M. Activation of the RAS/RAF/ERK signaling pathway contributes to resistance to sunitinib in thyroid carcinoma cell lines. J Clin Endocrinol Metab 2012; 97: E898-E906
    CrossrefPubMedGoogle Scholar